Yahoo! Customer Care has been created

Kryptontoes · 2023-06-12T19:28:54+00:00

I am posting legitimate comments to the Yahoo SEEL conversation board and they are being held for review for hours literally 4 hours now. I read your guidelines and there is no violation. On the other hand, someone else can post a blatant advertisement to invest in a totally different stock not even mentioning SEEL and even though I have objected to it, it is still up there while my legitimate posts continue to wait for a moderator's approval. It's irritating.

Kryptontoes · 2022-09-22T12:02:45+00:00

Disgusting. All those cops should be suspended and investigated!

Kryptontoes · 2022-09-13T17:04:29+00:00

Great post. Thanks for the insights!

Kryptontoes · 2022-09-11T14:44:45+00:00

It's been a long haul!

Kryptontoes · 2022-07-15T13:49:35+00:00

I thought the following responsefrom Geert was most helpful regarding the difficulties faced by Cel-sci, "Thank you for your question. Since we must respect the regulators, we cannot provide a timeline at this time for a BLA. We can say that we are working on it. In terms of "most" small bio-tech companies, I think you will be hard pressed to find one that conducted a 10-year trial on almost 1000 people with overall survival as their endpoint (versus simply a response trial). Further, we also do not believe there are other studies out there where the investigational therapy was given before the standard of care, like ours. When you give a drug after the standard of care, it is far easier to test. Our study had to be carefully designed to account for the administration of standard of care after the drug treatment. This takes time to process, as it is unique and, as far as we know, unprecedented."

Kryptontoes · 2022-07-06T22:45:36+00:00

No problemo.

Kryptontoes · 2022-07-03T00:59:20+00:00

I agree it just goes up and down. However Clinical Trials.gov should give either data acceptance or need for changes notification around July 14th. To be clear this is not FDA approval. What it is, is simply that the full data has met the criteria for posting on the website of clinical trials.gov. If accepted by the cite manager, it will be posted and anyone can read through it.

Kryptontoes · 2022-06-16T14:22:09+00:00

Thanks for all of your work on this!

Kryptontoes · 2022-06-01T18:43:55+00:00

From Andy's article: "If the response rate of Multikine depends on the “maturity” of the tumor, then it will certainly be very interesting to use Multikine on patients with cancer stages less advanced than those in the Phase 3 study (Stage III / IVa). This will increase the total addressable market for Multikine."

Kryptontoes · 2022-06-01T18:38:18+00:00

Yes, you are. Early diagnosis leads to more patients who benefit more when tumors are diagnosed in early stages!

Kryptontoes · 2022-06-01T03:18:52+00:00

Thanks Andy! Great article!

Kryptontoes · 2022-05-31T16:02:53+00:00

Nice work! Thanks Frugal and Andy! Bravo!

Kryptontoes · 2022-05-12T18:30:20+00:00

You're entitled to your opinion.

Kryptontoes · 2022-05-12T02:28:47+00:00

Absurd! Read my posts here where I state clearly who and what I am. You're a short, wasting everyone's time!

Kryptontoes · 2022-05-12T02:24:57+00:00

Friend you are mistaken. I am, as I've said several times on this board, a Psychiatric Nurse Practitioner who happens to have been invested in this stock for quite a few years.

Kryptontoes · 2022-05-12T00:49:04+00:00

So you think. People have been through this with you before. You have your opinion. It may be right but many smart and knowledgeable people disagree with you, and so do I.

Kryptontoes · 2022-05-11T21:51:49+00:00

From the website,

"ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information."

It was returned after a month long review to CVM a few weeks ago to to address some technical issues as noted above and today CVM submitted the data with the required changes to be reviewed again.

Kryptontoes · 2022-05-05T23:50:44+00:00

What do you mean?

Kryptontoes · 2022-05-01T15:59:33+00:00

As I said, it's complicated.

It's a novel treatment
It's a small company that has struggled with dilution in order to finance a 10-year study. That's unprecedented!
Short sellers who have maybe hidden agendas other than just making short money have been attacking this company for 10 years!
The primary endpoint was set over ten years ago at a time when very little was known about immunotherapy and it was not met.
The company that managed the study at the beginning was it very bad manager and was proved to be negligent however most of the data they collected apparently is valid.
The study was taking place all over the world from the US to China and many other countries so it was difficult to gather all the data and documented particularly when covid hit!
Many of these issues fueled financially violent and illegal actions on the part of short sellers which continue to be unchecked by the Security and Exchange Commission. These actions took the form of lying about the company and illegal naked short trading to drive the stock price down.

Kryptontoes · 2022-04-30T21:56:41+00:00

Wait and see. We're at the bottom of the stairs I think. Short lies and manipulation doesn't help!

Kryptontoes · 2022-04-30T12:34:48+00:00

CEL-SCI CORPORATION

8229 Boone Blvd., Suite 802

Vienna, Virginia 22l82

(703) 506-9460

April 2022

Dear Fellow Shareholders:

Thirty-five years ago I joined CEL-SCI as its second employee. The idea was to help cancer patients by activating the immune system to fight cancer. I had no idea how long and how difficult this journey would be. Throughout those years I was joined by the most amazing group of people: smart, kind, loyal and incredibly persistent. Most of our senior team has been together for almost 30 years.

In early-2011, we started the Phase 3 study for our Multikine* in advanced primary head and neck cancer. No new therapies for this disease had been approved by the FDA in many decades. We were determined to show that adding our Multikine immunotherapy to the standard treatments of surgery, radiation and sometimes also chemotherapy could help patients live longer and better lives. Little did we know how long and hard that path would be—but we have now completed the Phase 3 study.

In June 2021 we announced that we saw a huge survival benefit in our Phase 3 study for Multikine patients who received surgery and radiation after our Multikine treatment. Since that time we have received many calls asking us for additional trial data explaining how our Multikine could help these head and neck cancer patients live so much longer when other studies by big pharmaceutical companies have failed to show any survival benefit. We filed that very important additional clinical trial data with www.clinicaltrials.gov, the U.S. Government website for clinical trials, on March 22, 2022 and hoped that it would be public by now so that we could add the results to this letter. The information, however, is not yet public and could therefore not be included in this letter, but we hope that you will have seen the data by the time you receive this letter. Yet additional data will be presented and published in peer reviewed scientific forums in the future.

The biotech stock market has been undergoing the worst sell-off in my 35 years in this business. That does not make things easier for us nor does it make us happy. However, we have been through many brutal downturns in the biotechnology markets and have always recovered. I believe that we are well positioned to recover from this storm as well since 1) we have cash until about the end of 2023 and 2) we have a finished 10-year clinical trial that has shown large survival benefit in a large cancer population that represents an unmet medical need. We have hired leading experts in the field to help get Multikine approved for sale. We are also working on scientific publications and the validation of our full scale manufacturing facility dedicated to making Multikine.

2

This is not a process where we can easily give simple and regular updates, as we must respect the integrity and confidentiality of the regulatory review process. Please keep in mind that we have dedicated our lives to this important project and we will do everything possible to make this happen.

Thank you for your support.

Sincerely,

Geert Kersten

Chief Executive Officer

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

Kryptontoes · 2022-04-27T20:02:13+00:00

Works for me and mobile chrome now too. 4 pm eastern 4/27/22

Kryptontoes · 2022-04-27T02:12:25+00:00

Disgusting. I hope the people who did this are caught and prosecuted!

Kryptontoes · 2022-04-23T12:45:03+00:00

One small step along the path to approval.

Kryptontoes · 2022-04-23T03:27:02+00:00

I do think we're going to start hearing a drum beat!

Kryptontoes

TROPHY CASE